GE HealthCare Technologies Inc.

GEHC Healthcare Medical Devices

GE HealthCare Technologies Inc.’s revenue for fiscal 2025 (year ended December 2025) was $20.6 billion, up 4.84% from fiscal 2024.

Revenue
+7.19%
EPS
+40.6%
Free cash flow
+64.2%
Total debt
−1.90%

Quarter to September 2026, against a year earlier

82.39 1.36 −1.62%
Market cap
$37.9B
P/E
17.5×
Fwd P/E
15.5×
Dividend yield
0.17%
F-score
4/9
Altman Z
1.96
Beneish M
−2.33
Dividend safety
74/100

GE HealthCare Technologies Inc. 10-Q filed Oct 29, 2025

Fiscal Q3 2025 · Period ended Sep 30, 2025 · Filed · accepted 6:26 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 30, 2025: 14 added · 15 removed · 43 modified; 27 with only figures updated

  1. Removed

    Effective July 1, 2024, Image Guided Therapies, previously part of the Imaging segment, was realigned to the Ultrasound segment. The Ultrasound segment was subsequently renamed Advanced Visualization Solutions (“AVS”). Following this realignment, the Company continues to have four reportable segments: Imaging, Advanced Visualization Solutions, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. Historical segment financial information presented within this report has been recast to conform to the new reportable segments structure. For additional information on our segments, refer to Note 3, “Segment Information.”